130 related articles for article (PubMed ID: 17220044)
1. [Actions and safety of a 7-valent pneumococcal vaccine].
Med Monatsschr Pharm; 2006 Dec; 29(12):461-2. PubMed ID: 17220044
[No Abstract] [Full Text] [Related]
2. An expanded pneumococcal vaccine (prevnar 13) for infants and children.
Med Lett Drugs Ther; 2010 Aug; 52(1345):67-8. PubMed ID: 20724965
[No Abstract] [Full Text] [Related]
3. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine.
Center KJ; Hansen JR; Lewis E; Fireman BH; Hilton B
Pediatr Infect Dis J; 2009 May; 28(5):438-40. PubMed ID: 19319016
[TBL] [Abstract][Full Text] [Related]
4. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
van der Harst S
Ned Tijdschr Geneeskd; 2007 Aug; 151(33):1853-4; author reply 1854. PubMed ID: 17874645
[No Abstract] [Full Text] [Related]
5. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal conjugate vaccines. A review.
Galiza EP; Heath PT
Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
[TBL] [Abstract][Full Text] [Related]
8. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
Dinleyici EC; Yargic ZA
Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.
Dinleyici EC; Yargic ZA
Expert Rev Vaccines; 2008 Nov; 7(9):1367-94. PubMed ID: 18980540
[TBL] [Abstract][Full Text] [Related]
10. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
[TBL] [Abstract][Full Text] [Related]
11. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?
Moore MR; Whitney CG
Clin Infect Dis; 2008 Jan; 46(2):183-5. PubMed ID: 18171248
[No Abstract] [Full Text] [Related]
12. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
13. Experience with pneumococcal conjugate vaccine in Norway.
Aaberge IS
Expert Rev Vaccines; 2009 Feb; 8(2):159-65. PubMed ID: 19196196
[TBL] [Abstract][Full Text] [Related]
14. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination.
Vila-Córcoles A
J Intern Med; 2009 Nov; 266(5):432-44. PubMed ID: 19754854
[TBL] [Abstract][Full Text] [Related]
15. Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants.
O'Brien KL; David AB; Chandran A; Moulton LH; Reid R; Weatherholtz R; Santosham M
Pediatr Infect Dis J; 2008 Jan; 27(1):71-3. PubMed ID: 18162944
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
Adam D; Fehnle K
Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
18. Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives.
Bechini A; Boccalini S; Bonanni P
Vaccine; 2009 May; 27(25-26):3285-90. PubMed ID: 19200829
[TBL] [Abstract][Full Text] [Related]
19. 23-valent pneumococcal polysaccharide vaccine. WHO position paper.
Wkly Epidemiol Rec; 2008 Oct; 83(42):373-84. PubMed ID: 18927997
[No Abstract] [Full Text] [Related]
20. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).
Oosterhuis-Kafeja F; Beutels P; Van Damme P
Vaccine; 2007 Mar; 25(12):2194-212. PubMed ID: 17267077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
